Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Rang in Aktien #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Aktienkurs
$0.07339369
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$25.24M
Veränderung (1 Tag)
5.26%
Veränderung (1 Jahr)
-9.55%
Land
CA
Handel Resverlogix Corp. (RVX)

Kategorie

EPS für Resverlogix Corp. (RVX)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Resverlogix Corp. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Resverlogix Corp. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH